| B-cell immune dysregulation with low soluble CD22 levels in refractory seronegative myasthenia gravis. | B-cell immune dysregulation with low soluble CD22 levels in refractory seronegative myasthenia gravis.
Okuzono Y, Miyakawa S, Itou T, Sagara M, Iwata M, Ishizuchi K, Sekiguchi K, Motegi H, Oyama M, Warude D, Kikukawa Y, Suzuki S., Free PMC Article | 05/29/2024 |
| Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency. | Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency.
Aminov S, Giricz O, Melnekoff DT, Sica RA, Polishchuk V, Papazoglu C, Yates B, Wang HW, Sahu S, Wang Y, Gordon-Mitchell S, Leshchenko VV, Schinke C, Pradhan K, Aluri S, Sohn M, Barta SK, Agarwal B, Goldfinger M, Mantzaris I, Shastri A, Matsui W, Steidl U, Brody JD, Shah NN, Parekh S, Verma A., Free PMC Article | 05/1/2024 |
| Deciphering prognostic value of CD22 and its contribution to suppression of proinflammatory cytokines production in patients with IgA nephropathy. | Deciphering prognostic value of CD22 and its contribution to suppression of proinflammatory cytokines production in patients with IgA nephropathy.
Liu Y, Li H, Yu H, Wang F, Cao H, Jia J, Yan T. | 03/31/2023 |
| Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer's disease. | Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer's disease.
Bu XL, Sun PY, Fan DY, Wang J, Sun HL, Cheng Y, Zeng GH, Chen DW, Li HY, Yi X, Shen YY, Miles LA, Maruff P, Gu BJ, Fowler CJ, Masters CL, Wang YJ., Free PMC Article | 04/16/2022 |
| CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. | CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S, Vora A, Bonney D, Veys P, Rao K, Lucchini G, Chiesa R, Chu J, Clark L, Fung MM, Smith K, Peticone C, Al-Hajj M, Baldan V, Ferrari M, Srivastava S, Jha R, Arce Vargas F, Duffy K, Day W, Virgo P, Wheeler L, Hancock J, Farzaneh F, Domning S, Zhang Y, Khokhar NZ, Peddareddigari VGR, Wynn R, Pule M, Amrolia PJ., Free PMC Article | 11/13/2021 |
| Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments. | Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments.
Gsottberger F, Brandl C, Wendland K, Petkovic S, Emmerich C, Erber R, Geppert C, Hartmann A, Mackensen A, Nitschke L, Müller F., Free PMC Article | 10/30/2021 |
| The Protein Tyrosine Phosphatase SHP-1 (PTPN6) but Not CD45 (PTPRC) Is Essential for the Ligand-Mediated Regulation of CD22 in BCR-Ligated B Cells. | The Protein Tyrosine Phosphatase SHP-1 (PTPN6) but Not CD45 (PTPRC) Is Essential for the Ligand-Mediated Regulation of CD22 in BCR-Ligated B Cells.
Alborzian Deh Sheikh A, Akatsu C, Abdu-Allah HHM, Suganuma Y, Imamura A, Ando H, Takematsu H, Ishida H, Tsubata T. | 10/2/2021 |
| Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B-Cell Lymphoma Therapy. | Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B-Cell Lymphoma Therapy.
Hong S, Yu C, Wang P, Shi Y, Cao W, Cheng B, Chapla DG, Ma Y, Li J, Rodrigues E, Narimatsu Y, Yates JR 3rd, Chen X, Clausen H, Moremen KW, Macauley MS, Paulson JC, Wu P., Free PMC Article | 03/28/2021 |
| Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia. | Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia.
Ryland GL, Barraclough A, Fong CY, Fleming S, Bajel A, Hofmann O, Westerman D, Grimmond S, Blombery P. | 03/20/2021 |
| Humanized CD22 transgenic mouse model for in vivo analysis of anti-CD22-based immunotherapy. | Humanized CD22 transgenic mouse model for in vivo analysis of anti-CD22-based immunotherapy.
Brandl C, Angermüller S, Nitschke L. | 02/6/2021 |
| N-Linked Glycosylation Regulates CD22 Organization and Function. | N-Linked Glycosylation Regulates CD22 Organization and Function.
Wasim L, Buhari FHM, Yoganathan M, Sicard T, Ereño-Orbea J, Julien JP, Treanor B., Free PMC Article | 09/19/2020 |
| CD22 plays a key role in affecting B cell responses to antigens and innate immune signals, and CD22-CD22L interactions are essential for maintaining self-tolerance. The ability of CD22 to regulate both B cell receptor and toll-like receptors represents an attractive therapeutic strategy for manipulating B cell responses in autoimmunity. | CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity.
Clark EA, Giltiay NV., Free PMC Article | 10/26/2019 |
| Authors semi-quantitatively classified baseline expression of sCD19 and sCD22 in a large cohort of pediatric B-ALL. Dim CD19 and negative CD22 cases were correlated with common genetic abnormalities. | Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia.
Rosenthal J, Naqvi AS, Luo M, Wertheim G, Paessler M, Thomas-Tikhonenko A, Rheingold SR, Pillai V. | 08/24/2019 |
| up-regulation of siglec-2 in tumor tissues could predict better overall survival (OS) in hepatocellular carcinoma patients. Mechanisms of siglec-2 in hepatocellular carcinoma (HCC) development need further research. | Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus.
Ren X, Ji Y, Jiang X, Qi X., Free PMC Article | 07/20/2019 |
| Conjugates of these multivalent ligands with auristatin and saporin toxins are efficiently internalized via hCD22 resulting in killing of B-cell lymphoma cells | CD22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma Cells.
Peng W, Paulson JC., Free PMC Article | 06/16/2018 |
| This is the first time a NMR-based binding study of high affinity Siglec-2 (CD22) ligands in complex with whole Burkitt's lymphoma Daudi cells has been described. | Structural characterisation of high affinity Siglec-2 (CD22) ligands in complex with whole Burkitt's lymphoma (BL) Daudi cells by NMR spectroscopy.
Madge PD, Maggioni A, Pascolutti M, Amin M, Waespy M, Bellette B, Thomson RJ, Kelm S, von Itzstein M, Haselhorst T., Free PMC Article | 05/5/2018 |
| Here the authors structurally characterize the ectodomain of CD22 and present its crystal structure with the bound therapeutic antibody epratuzumab, which gives insights into the mechanism of inhibition of B-cell activation. | Molecular basis of human CD22 function and therapeutic targeting.
Ereño-Orbea J, Sicard T, Cui H, Mazhab-Jafari MT, Benlekbir S, Guarné A, Rubinstein JL, Julien JP., Free PMC Article | 01/13/2018 |
| hCD22 transgenic mice develop normal humoral responses in a peanut allergy oral sensitization model. Homing of B cells to Peyer's patches was partially rescued by expression of hCD22 compared with CD22(-/-) B cells, although not to wild-type levels. | Human CD22 Inhibits Murine B Cell Receptor Activation in a Human CD22 Transgenic Mouse Model.
Bednar KJ, Shanina E, Ballet R, Connors EP, Duan S, Juan J, Arlian BM, Kulis MD, Butcher EC, Fung-Leung WP, Rao TS, Paulson JC, Macauley MS., Free PMC Article | 10/28/2017 |
| Diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy reduced disease burden in a non-Hodgkin lymphoma mouse model. | Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
Weber T, Bötticher B, Arndt MA, Mier W, Sauter M, Exner E, Keller A, Krämer S, Leotta K, Wischnjow A, Grosse-Hovest L, Strumberg D, Jäger D, Gröne HJ, Haberkorn U, Brem G, Krauss J. | 07/29/2017 |
| Siglec-1 and Siglec-2 are potential biomarkers in autoimmune disease. (Review) | Siglec-1 and -2 as potential biomarkers in autoimmune disease.
Eakin AJ, Bustard MJ, McGeough CM, Ahmed T, Bjourson AJ, Gibson DS. | 04/22/2017 |
| We aimed to screen exons 9-14 of the CD22 gene, which is a mutational hot spot region in B-precursor acute lymphoblastic leukemia (pre-B ALL) patients. Nine variants, of which two novel, were found. Novel variants were in introns 10 and 13. Gly745Asp (rs10406069) variant was missense and Cys790Arg (rs79438722) variant was silent. | Screening of Variations in CD22 Gene in Children with B-Precursor Acute Lymphoblastic Leukemia.
Aslar Oner D, Akin DF, Sipahi K, Mumcuoglu M, Ezer U, Kürekci AE, Akar N. | 04/8/2017 |
| Anti-CD22-magnetic nanoparticles-doxorubicin inhibited the proliferation of Raji cells, significantly increased the uptake of doxorubicin, and induced apoptosis. | Novel synthesizing method of pH-dependent doxorubicin-loaded anti-CD22-labelled drug delivery nanosystem.
Sun M, Wang J, Lu Q, Xia G, Zhang Y, Song L, Fang Y., Free PMC Article | 07/16/2016 |
| results demonstrate that loss of high affinity CD22 ligands on GC B-cells occurs in both mice and humans through alternative mechanisms, unmasking CD22 relative to naive and memory B-cells | Unmasking of CD22 Co-receptor on Germinal Center B-cells Occurs by Alternative Mechanisms in Mouse and Man.
Macauley MS, Kawasaki N, Peng W, Wang SH, He Y, Arlian BM, McBride R, Kannagi R, Khoo KH, Paulson JC., Free PMC Article | 05/14/2016 |
| MicroRNA-19a and CD22 Comprise a Feedback Loop for B Cell Response in Sepsis. | MicroRNA-19a and CD22 Comprise a Feedback Loop for B Cell Response in Sepsis.
Jiang Y, Zhou H, Ma D, Chen ZK, Cai X., Free PMC Article | 02/27/2016 |
| These results suggest that the in vivo mechanism of non-ligand-blocking epratuzumab may, in part, involve the unmasking of CD22 to facilitate the trans-interaction of B cells with vascular endothelium. | Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.
Chang CH, Wang Y, Gupta P, Goldenberg DM., Free PMC Article | 10/3/2015 |